Zacks Investment Management Arcus Biosciences, Inc. Transaction History

Zacks Investment Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $472,108 - $742,299	-20,752 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$26.16 - $41.39 $542,872 - $858,925	20,752 New	20,752 $583,000
Q3 2020 Nov 16, 2020	SELL	$17.14 - $25.47 $244,125 - $362,769	-14,243 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $198,974 - $520,724	14,243 New	14,243 $352,000

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

Stay updated on Zacks Investment Management with notifications on news.